Compare PXS & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXS | PASG |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 27.6M |
| IPO Year | N/A | 2020 |
| Metric | PXS | PASG |
|---|---|---|
| Price | $3.06 | $8.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 25.4K | ★ 42.1K |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,491,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.47 | $5.12 |
| 52 Week High | $4.40 | $26.60 |
| Indicator | PXS | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 68.80 | 53.47 |
| Support Level | $2.63 | $7.13 |
| Resistance Level | $3.13 | $9.20 |
| Average True Range (ATR) | 0.10 | 1.02 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 85.94 | 59.72 |
Pyxis Tankers Inc is an international maritime transportation company focused on mid-sized eco-vessels for the product tanker and dry-bulk sectors. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Konkar Ormi, Pyxis Lamda, Konkar Venture, Pyxis Karteria, and others. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals. The company operates under two reportable segments, Tanker Vessels, which derive maximum revenue, and Dry-bulk Vessels.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.